COVID-19 e hipertension arterial: ¿existe evidencia para suspender antagonista sistema renina angiotensina?

Autor:	Luis Puello González, María de los Angeles Velez Verbel, Laura María Gómez Franco, Roberto Ramirez Marmolejo, Joaquín Rodelo Ceballos, Ignacio Villanueva Bendek, Juan Diego Montejo
Rok vydání:	2020
Předmět:	biology business.industry Angiotensin-converting enzyme Disease Pharmacology medicine.disease medicine.disease_cause Pathophysiology Nephrology Diabetes mellitus Renin–angiotensin system medicine biology.protein In patient Receptor business Coronavirus
Zdroj:	Revista Colombiana de Nefrología. 7:21-22
ISSN:	2500-5006 2389-7708
DOI:	10.22265/acnef.7.supl.2.405
Popis:	The new coronavirus SARS-CoV-2, which causes the disease COVID-19, has a high mortality in patients with cardiovascular diseases, diabetes and hypertension, disorders that share the underlying pathophysiology related to the renin-angiotensin system (RAS). SARS-CoV-2 uses the membrane protein angiotensin I and converts angiotensin converting enzyme type 2 (ACE2) into a cellular entry receptor, therefore, RAS, regulated by ACE and ACE2, can be altered in COVID-19 patients. However, it is not yet clear whether the use of antihypertensive drugs ACE2 inhibitors and angiotensin II receptor blockers could potentiate the damage caused by the virus or counteract its effect, especially in the lungs. The challenge is compounded by the exaggerated information published in different scientific journals, which could lead to inappropriate actions, so it is important to quickly differentiate the true epidemic from false hypotheses, which could lead to potentially harmful medical behaviors.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::dd446206f64b7878dbdbe25069b59219 https://doi.org/10.22265/acnef.7.supl.2.405 Zobrazit plný text záznamu